Cytokeratin 7: A re-evaluation of the 'tried and true' in triple-negative breast cancers

Histopathology

Volumn 61, Issue 4, 2012, Pages 660-666

  Davion, Simone M ^a   Siziopikou, Kalliopi P ^a   Sullivan, Megan E ^a  

^a NORTHWESTERN MEMORIAL HOSPITAL   (United States)

Author keywords

Basal like; Cytokeratin 20; Cytokeratin 5 6; Cytokeratin 7; GCDFP 15; Invasive ductal carcinoma; Mammaglobin; Triple negative; Unknown primary

Indexed keywords

CYTOKERATIN 20; CYTOKERATIN 5; CYTOKERATIN 6; CYTOKERATIN 7; GROSS CYSTIC DISEASE FLUID PROTEIN 15; MAMMAGLOBIN; PROTEIN; UNCLASSIFIED DRUG; TUMOR MARKER;

ADENOID CYSTIC CARCINOMA; ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER CELL; CANCER SIZE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INVASIVE CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; METAPLASIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE MICROARRAY; TRIPLE NEGATIVE BREAST CANCER; BIOSYNTHESIS; FEMALE; METABOLISM; MIDDLE AGED; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KERATIN-7; MIDDLE AGED; TISSUE ARRAY ANALYSIS; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84871918427     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2012.04253.x     Document Type: Article

References (33)

1. Badve S, Dabbs DJ, Schnitt SJ et al. Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists. Mod. Pathol. 2011;24; 157-167.
2. Sorlie T, Perou CM, Tibshirani R et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl Acad. Sci. USA 2001; 98;10869-10874.
3. Dent R, Hanna WM, Trudeau M, Rawlinson E, Sun P, Narod SA. Pattern of metastatic spread in triple-negative breast cancer. Breast Cancer Res. Treat. 2009; 115; 423-428.
4. Jarasch ED, Nagle RB, Kaufmann M, Maurer C, Bocker WJ. Differential diagnosis of benign epithelial proliferations and carcinomas of the breast using antibodies to cytokeratins. Hum.Pathol. 1988; 19; 276-289.
5. Moll R. Cytokeratins as markers of differentiation in the diagnosis of epithelial tumors. Subcell. Biochem. 1998; 31; 205-262.
6. Moll R. Molecular diversity of cytokeratins: significance for cell and tumor differentiation. Acta Histochem. Suppl. 1991; 41; 117-127.
7. Cooper D, Schermer A, Sun TT. Classification of human epithelia and their neoplasms using monoclonal antibodies to keratins:strategies, applications, and limitations. Lab. Invest. 1985; 52;243-256.
8. Perou CM, Sorlie T, Eisen MB et al. Molecular portraits of human breast tumours. Nature 2000; 406; 747-752.
9. Malzahn K, Mitze M, Thoenes M, Moll R. Biological and prognostic significance of stratified epithelial cytokeratins in infiltrating ductal breast carcinomas. Virchows Arch. 1998; 433;119-129.
10. Ramaekers F, Van Niekerk C, Poels L et al. Use of monoclonal antibodies to keratin 7 in the differential diagnosis of adenocarcinomas.Am. J. Pathol. 1990; 136; 641-655.
11. Tot T. Adenocarcinomas metastatic to the liver: the value of cytokeratins 20 and 7 in the search for unknown primary tumors. Cancer 1999; 85; 171-177.
12. Tot T. Cytokeratins 20 and 7 as biomarkers: usefulness in discriminating primary from metastatic adenocarcinoma. Eur. J. Cancer 2002; 38; 758-763.
13. Tot T. The value of cytokeratins 20 and 7 in discriminating metastatic adenocarcinomas from pleural mesotheliomas. Cancer 2001; 92; 2727-2732.
14. Chu P, Wu E, Weiss LM. Cytokeratin 7 and cytokeratin 20 expression in epithelial neoplasms: a survey of 435 cases. Mod.Pathol. 2000; 13; 962-972.
15. Wang NP, Zee S, Zarbo RJ, Bacchi CE, Gown AM. Coordinate expression of cytokeratins 7 and 20 defines unique subsets of carcinomas. Appl. Immunohistochem. Mol. Morphol. 1995; 3; 99-107.
16. Lagendijk JH, Mullink H, Van Diest PJ, Meijer GA, Meijer CJ. Immunohistochemical differentiation between primary adenocarcinomas of the ovary and ovarian metastases of colonic and breast origin. Comparison between a statistical and an intuitive approach. J. Clin. Pathol. 1999; 52; 283-290.
17. Haagensen DE Jr, Mazoujian G, Dilley WG, Pedersen CE, Kister SJ, Wells SA Jr.. Breast gross cystic disease fluid analysis I. Isolation and radioimmunoassay for a major component protein. J. Natl Cancer Inst. 1979; 62; 239-247.
18. Clark JW, Snell L, Shiu RP et al. The potential role for prolactininducible protein (PIP) as a marker of human breast cancer micrometastasis. Br. J. Cancer 1999; 81; 1002-1008.
19. Kaufmann O, Fietze E, Dietel M. Immunohistochemical diagnosis in cancer metastasis of unknown primary tumor. Pathologe2002; 23; 183-197.
20. Bhargava R, Beriwal S, Dabbs DJ. Mammaglobin vs GCDFP-15:an immunohistologic validation survey for sensitivity and specificity. Am. J. Clin. Pathol. 2007; 127; 103-113.
21. Lewis GH, Subhawong AP, Nassar H et al. Relationship between molecular subtype of invasive breast carcinoma and expression of gross cystic disease fluid protein 15 and mammaglobin. Am. J.Clin. Pathol. 2011; 135; 587-591.
22. Watson MA, Fleming TP. Mammaglobin, a mammary-specific member of the uteroglobin gene family, is overexpressed in human breast cancer. Cancer Res. 1996; 56; 860-865.
23. Fleming TP, Watson MA. Mammaglobin, a breast-specific gene, and its utility as a marker for breast cancer. Ann. N Y Acad. Sci.2000; 923; 78-89.
24. Yang M, Nonaka D. A study of immunohistochemical differential expression in pulmonary and mammary carcinomas. Mod.Pathol. 2010; 23; 654-661.
25. Nielsen TO, Hsu FD, Jensen K et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin. Cancer Res. 2004; 10; 5367-5374.
26. Livasy CA, Karaca G, Nanda R et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod. Pathol.2006; 19; 264-271.
27. Moll R, Lowe A, Laufer J, Franke WW. Cytokeratin 20 in human carcinomas. A new histodiagnostic marker detected by monoclonal antibodies. Am. J. Pathol. 1992; 140; 427-447.
28. Sasaki E, Tsunoda N, Hatanaka Y, Mori N, Iwata H, Yatabe Y. Breast-specific expression of MGB1/mammaglobin: an examination of 480 tumors from various organs and clinicopathological analysis of MGB1-positive breast cancers. Mod. Pathol. 2007; 20;208-214.
29. Fritzsche FR, Thomas A, Winzer KJ et al. Co-expression and prognostic value of gross cystic disease fluid protein 15 and mammaglobin in primary breast cancer. Histol. Histopathol.2007; 22; 1221-1230.
30. Span PN, Waanders E, Manders P et al. Mammaglobin is associated with low-grade, steroid receptor-positive breast tumors from postmenopausal patients, and has independent prognostic value for relapse-free survival time. J. Clin. Oncol.2004; 22; 691-698.
31. Guan XF, Hamedani MK, Adeyinka A et al. Relationship between mammaglobin expression and estrogen receptor status in breast tumors. Endocrine 2003; 21; 245-250.
32. Nunez-Villar MJ, Martinez-Arribas F, Pollan M et al. Elevated mammaglobin (h-MAM) expression in breast cancer is associated with clinical and biological features defining a less aggressive tumour phenotype. Breast Cancer Res. 2003; 5;R65-R70.
33. Pagani A, Sapino A, Eusebi V, Bergnolo P, Bussolati G.PIP/GCDFP-15 gene expression and apocrine differentiation in carcinomas of the breast. Virchows Arch. 1994; 425; 459-465.